Trials / Unknown
UnknownNCT05607693
A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects
A Multi-Center, Open- Label, Single-Arm Phase 1 QT/QTc Study of SHR3680 in Subjects With Castration-Resistant Prostate Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR3680 tablets | Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible. |
Timeline
- Start date
- 2023-04-26
- Primary completion
- 2024-11-05
- Completion
- 2024-11-05
- First posted
- 2022-11-07
- Last updated
- 2023-05-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05607693. Inclusion in this directory is not an endorsement.